Ruilin He

Dr. Ruilin He


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
LWLiu Wang
Liu Wang
ZLZhixuan Lan
Zhixuan Lan
YHYing He
Ying He
YCYue Cheng
Yue Cheng
RHRuilin He
Ruilin He
ZJZongbin Jiang
Zongbin Jiang
Migraine is a debilitating neurological disorder. Emerging evidence suggests that metabolic dysregulation and immune dysfunction contribute to migraine pathogenesis while the molecular mechanisms linking these processes remain unclear. Lactylation may serve as a crucial integrator of metabolic and immune signals in migraine. We performed a comprehensive multi-omics Mendelian randomization study integrating DNA methylation, gene expression, and protein abundance data with genome-wide association studies on migraine. Summary-data-based Mendelian randomization, Bayesian colocalization, and two-sample MR analyses were conducted to identify lactylation-related genes causally associated with migraine. We further explored immune cell mediation using genetic data from 731 immune phenotypes and validated findings through single-cell RNA sequencing of peripheral blood mononuclear cells from migraine patients and controls. EP300, SIRT1, and SLC16A1 were identified as key regulators of migraine susceptibility across methylation, expression, and protein levels. EP300 and SLC16A1 were associated with increased migraine risk, while SIRT1 conferred a protective effect. Mediation analyses revealed that genetic effects of these genes were partially transmitted through specific immune cell subsets, particularly B cells and natural killer T cells. Single-cell transcriptomic profiling further demonstrated EP300 upregulation in B cells and T cells of migraine patients. These findings support a novel “lactylation–immune mediation–migraine axis” linking metabolic and immune dysregulation to migraine pathogenesis. This integrative multi-omics analysis uncovers lactylation-related genes as causal drivers of migraine through immunometabolic pathways. Targeting lactylation-regulated metabolic and immune mechanisms may offer novel precision therapeutic strategies for migraine, particularly in patients with inflammatory or metabolic endophenotypes.

7 November 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
LWLiu Wang
Liu Wang
XLXiaoxiao Lan
Xiaoxiao Lan
ZLZhixuan Lan
Zhixuan Lan
SXShengrong Xu
Shengrong Xu
RHRuilin He
Ruilin He
ZJZongbin Jiang
Zongbin Jiang
Background: The varicella-zoster virus (VZV) can cause herpes zoster (HZ), which may progress to postherpetic neuralgia (PHN), leading to severe inflammatory responses and pain.Objective: This study investigates the relationship between pain duration characteristics and pain intensity in patients with herpes zoster-related pain, hypothesizing that persistent pain correlates with higher pain intensity compared to intermittent pain.Methods: A retrospective study was conducted at the Second Affiliated Hospital of Guangxi Medical University, China. Data from patients treated for herpes zoster-related pain between January 2019 and February 2024 were analyzed. Pain intensity was measured using the Numerical Rating Scale (NRS-11), and pain duration was categorized as intermittent or persistent. Multivariate regression models were used to assess the association between pain duration and intensity, adjusting for potential confounders.Results: A total of 840 patients were included. Persistent pain was significantly associated with higher NRS-11 scores compared to intermittent pain (β = 0.71, 95% CI 0.50–0.91, p < 0.001). Subgroup analyses showed that persistent pain was associated with higher pain intensity in both acute HZ and PHN patients (HZ: β = 0.71, 95% CI 0.45–0.96, p < 0.001; PHN: β = 0.76, 95% CI 0.40–1.13, p < 0.001). Inflammatory markers, such as C-reactive protein (CRP) and white blood cell count, were positively correlated with pain intensity.Conclusion: Pain duration significantly impacts pain intensity in HZ patients. Considering pain duration is crucial for effective pain management. Further research should explore the mechanisms underlying persistent pain to develop better treatment strategies.

7 January 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
LWLiu Wang
Liu Wang
SXShengrong Xu
Shengrong Xu
ZJZongbin Jiang
Zongbin Jiang
RHRuilin He
Ruilin He
Background: Herpes zoster (HZ) patients often experience herpes zoster-associated pain (ZAP). Thoracic paravertebral nerve block has been proven effective in relieving ZAP and reducing the incidence of postherpetic neuralgia (PHN). Compared to dexamethasone, dexamethasone palmitate (DXP) has stronger anti-inflammatory effects, a longer duration of action, and fewer adverse reactions. This study evaluates the efficacy and safety of ultrasound-guided thoracic paravertebral injection of DXP combined with ropivacaine for treating thoracic ZAP, compared to traditional famciclovir therapy.Methods: This prospective, randomized, controlled, open-label, endpoint-blinded, single-center trial will recruit 254 patients with ZAP. Patients will be randomly assigned in a 1:1 ratio to the intervention group (thoracic paravertebral injections of DXP combined with ropivacaine and antiviral therapy) or the control group (antiviral therapy). Assessments will include pain intensity, quality of life, sleep quality, inflammatory markers, and adverse events.Ethics and registration: This study strictly adheres to the 2013 SPIRIT Statement and the Declaration of Helsinki and has been approved by the Ethics Committee of the Second Affiliated Hospital of Guangxi Medical University (Approval Number: 2024-KY(0505)). This clinical trial is registered on the Chinese Clinical Trial Registry platform (ChiCTR) at https://www.chictr.org.cn/index.html (ChiCTR2400087273), registered on 2024-07-24. The results will be disseminated through scientific journals and conferences, aiming to provide evidence supporting the global management of ZAP. The study is expected to start on 1 August 2024, and continue until 31 July 2027.

12 December 2024 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
LWLiu Wang
Liu Wang
XLXinyu Lei
Xinyu Lei
ZLZhixuan Lan
Zhixuan Lan
RHRuilin He
Ruilin He
ZJZongbin Jiang
Zongbin Jiang
Background: Herpes zoster (HZ), triggered by the reactivation of the varicella-zoster virus, manifests as a painful rash known as zoster-associated pain (ZAP), which can progress to postherpetic neuralgia (PHN). This study evaluates the efficacy and safety of ultrasound-guided thoracic paravertebral injections of platelet-rich plasma (PRP) in managing acute ZAP and preventing PHN. Methods: This is a prospective, randomized, controlled, open-label, endpoint-blinded, single-center trial involving 128 participants suffering from zoster-associated pain. Participants will be randomly assigned to the PRP treatment in combination with antiviral therapy group or the antiviral therapy group at a 1:1 ratio. Pain intensity (NRS-11), quality of life (SF-12), sleep quality (PSQI), pain characteristics, skin lesion recovery, average weekly consumption of rescue analgesics, and adverse events will be assessed. Follow-up assessments will be conducted at 1, 3, 6, and 12 months post-intervention to evaluate the incidence rate of PHN, pain intensity, quality of life, sleep quality, and safety. Ethics and Dissemination: Adhering to the 2013 SPIRIT statement and the Declaration of Helsinki, this study has received ethical approval from the relevant committee. Results will be disseminated through scientific journals and conferences, contributing to global data on managing ZAP. Conclusions: By comparing PRP with antiviral therapy, this trial seeks to establish a more effective treatment paradigm for reducing acute zoster-associated pain and the incidence of PHN, potentially setting a new standard in therapeutic strategies for HZ. Trial Registration: This clinical trial is registered with the Chinese Clinical Trial Registry (ChiCTR) at https://www.chictr.org.cn/index.html (Registration Number: ChiCTR2400087248, Registration Date: 2024–07-23).

14 February 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LWLiu Wang
Liu Wang
ALAiguo Li
Aiguo Li
ZLZhixuan Lan
Zhixuan Lan
SXShengrong Xu
Shengrong Xu
RHRuilin He
Ruilin He
ZJZongbin Jiang
Zongbin Jiang
Herpes zoster has a well-established increased incidence in older adults, but the relationship between age and acute pain severity remains less clear. This retrospective study aimed to explore the association between age and pain intensity in Herpes zoster patients. A total of 613 patients treated at the Second Affiliated Hospital of Guangxi Medical University were included. Pain intensity was measured using the Numerical Rating Scale-11, and statistical models were applied to evaluate age-related pain differences while controlling for confounders. While older age was associated with higher pain scores (β = 0.02, p < 0.001), the effect size was small. Other factors, such as pain duration and inflammatory markers (e.g., CRP levels), showed stronger associations with pain severity. These findings suggest that age may not be the dominant factor in Herpes zoster pain severity, and a more comprehensive approach is required for risk assessment and pain management in clinical practice.

5 August 2025 in Obesity Research & Clinical Practice
Verified
Journal Article
Open access
XLXinyu Lei
Xinyu Lei
LWLiu Wang
Liu Wang
RHRuilin He
Ruilin He
ZJZongbin Jiang
Zongbin Jiang
To examine the association between waist-to-height ratio (WHtR), a marker of central adiposity, and the odds of frequent or severe headaches, including migraines, in U.S. children and adolescents. We analyzed 8915 participants aged 8-19 years in the 1999-2004 National Health and Nutrition Examination Survey (NHANES). WHtR was calculated as waist circumference divided by height and scaled by 10 to reflect the effect of a 0.1-unit increase. We applied survey-weighted logistic regression models to estimate associations between WHtR and self-reported headache status, adjusting for demographic, metabolic, and behavioral covariates. Additional interaction and sensitivity analyses were conducted to assess effect modification and robustness. Each 0.1-unit increase in WHtR was associated with a 26 % higher odds of reporting headaches (OR = 1.26, 95 % CI: 1.15, 1.38; p < 0.001). Compared to the lowest quartile (Q1), participants in the highest quartile (Q4) had 34 % greater odds (OR = 1.34, 95 % CI: 1.06, 1.70). Restricted cubic spline models demonstrated a linear dose-response association (p for nonlinearity = 0.96). The association remained robust across multiple sensitivity analyses. WHtR was linearly associated with the odds of frequent or severe headaches in U.S. youth. Although the cross-sectional design limits causal inference, WHtR may serve as a simple and developmentally stable marker for identifying obesity-related neurological symptoms, warranting further longitudinal investigation.